Genomic aberrations in pediatric gliomas and embryonal tumors

✍ Scribed by Hanne-Sofie S. Dahlback; Petter Brandal; Ludmila Gorunova; Eva Widing; Torstein R. Meling; Bård K. Krossnes; Sverre Heim

• Publisher: John Wiley and Sons
• Year: 2011
• Tongue: English
• Weight: 449 KB
• Volume: 50
• Category: Article
• ISSN: 1045-2257
• DOI: 10.1002/gcc.20898

✦ Synopsis

Abstract

The pathogenesis of pediatric central nervous system tumors is poorly understood. To increase knowledge about the genetic mechanisms underlying these tumors, we performed genome‐wide screening of 17 pediatric gliomas and embryonal tumors combining G‐band karyotyping and array comparative genomic hybridization (aCGH). G‐banding revealed abnormal karyotypes in 56% of tumor samples (9 of 16; one failed in culture), whereas aCGH found copy number aberrations in all 13 tumors examined. Pilocytic astrocytomas (n = 3) showed normal karyotypes or nonrecurrent translocations by karyotyping but the well‐established recurrent gain of 7q34 and 19p13.3 by aCGH. Our series included one anaplastic oligoastrocytoma, a tumor type not previously characterized genomically in children, and one anaplastic neuroepithelial tumor (probably an oligoastrocytoma); both showed loss of chromosome 14 by G‐banding and structural aberrations of 6q and loss of 14q, 17p, and 22q by aCGH. Three of five supratentorial primitive neuroectodermal tumors showed aberrant karyotypes: two were near‐diploid with mainly structural changes and one was near‐triploid with several trisomies. aCGH confirmed these findings and revealed additional recurrent gains of 1q21‐44 and losses of 3p21, 3q26, and 8p23. We describe cytogenetically for the first time a cribriform neuroepithelial tumor, a recently identified variant of atypical teratoid/rhabdoid tumor with a favorable prognosis, which showed loss of 1p33, 4q13.2, 10p12.31, 10q11.22, and 22q by aCGH. This study indicates the existence of distinct cytogenetic patterns in pediatric gliomas and embryonal tumors; however, further studies of these rare tumors using a multimodal approach are required before their true genomic aberration pattern can be finally established. © 2011 Wiley‐Liss, Inc.